Table 1.
Baseline characteristics of the study population.
| All patients (N = 231) | mRS ≤ 3 (N = 79) | mRS > 3 (N = 152) | P | |
|---|---|---|---|---|
| Age, years, mean ± SD | 62.74 ± 12.18 | 61.23 ± 13.35 | 63.52 ± 11.49 | 0.175 |
| Men, (n%) | 172 (74.46) | 56 (70.89) | 116 (76.32) | 0.460 |
| Baseline NIHSS, median (IQR) | 26.0 (17.0–32.0) | 23.0 (11.0–30.0) | 29.0 (20.0–34.0) | <0.001 |
| Initial PC-ASPECTS, median (IQR) | 8 (7–9) | 9 (8–10) | 7 (6–8) | <0.001 |
| Admission SBP, mmHg, mean ± SD | 144.94 ± 23.42 | 146.52 ± 23.72 | 144.12 ± 23.30 | 0.461 |
| Admission DBP, mmHg, mean ± SD | 83.86 ± 15.17 | 83.38 ± 16.09 | 84.11 ± 14.71 | 0.729 |
| 24 h NIHSS after EVT, median (IQR) | 27.0 (12.0–34.0) | 9.0 (3.0–17.5) | 32.0 (23.0–35.0) | <0.001 |
| 7 d NIHSS after EVT, median(IQR) | 19.0 (6.5–35.0) | 3.0 (1.0–8.0) | 31.5 (18.0–36.0) | <0.001 |
| Pre-onset mRS | ||||
| 0 | 206 (89.18) | 71 (89.87) | 135 (88.82) | 0.794 |
| 1 | 20 (8.66) | 7 (8.86) | 13 (8.55) | |
| 2 | 5 (2.16) | 1 (1.27) | 4 (2.63) | |
| BPV/CFV | 3.20 (0.45) | 3.30 (0.41) | 3.16 (0.47) | 0.022 |
| History of risk factors, n(%) | ||||
| Hypertension | 152 (65.80) | 56 (70.89) | 96 (63.16) | 0.304 |
| Diabetes mellitus | 53 (22.94) | 16 (20.25) | 37 (24.34) | 0.592 |
| Dyslipidemia | 73 (31.60) | 30 (37.97) | 43 (28.29) | 0.176 |
| Atrial fibrillation | 45 (19.48) | 19 (24.05) | 26 (17.11) | 0.276 |
| Smoking | 85 (36.80) | 32 (40.51) | 53 (34.87) | 0.484 |
| TIA | 5 (2.16) | 1 (1.27) | 4 (2.63) | 0.841 |
| TOAST classification, n(%) | 0.262 | |||
| LAA | 151 (65.37) | 45 (56.96) | 106 (69.74) | |
| CE | 58 (25.11) | 25 (31.65) | 33 (21.71) | |
| SOE | 6 (2.60) | 2 (2.53) | 4 (2.63) | |
| SUE | 16 (6.93) | 7 (8.86) | 9 (5.92) | |
| Imaging parameters | ||||
| Occlusion site, n (%) | 0.044 | |||
| BA distal | 76 (32.90) | 34 (43.04) | 42 (27.63) | |
| BA middle | 70 (30.30) | 16 (20.25) | 54 (35.53) | |
| BA proximal | 42 (18.18) | 13 (16.46) | 29 (19.08) | |
| V4 | 43 (18.61) | 16 (20.25) | 27 (17.76) | |
| PC-CS score, median (IQR) | 4 (3–6) | 5 (4–6) | 4 (3–6) | <0.001 |
| Treatment procedure, n(%) | ||||
| Intravenous thrombolysis | 49 (21.21) | 15 (18.99) | 34 (22.37) | 0.330 |
| Anesthesia | 0.450 | |||
| General | 83 (35.93) | 31 (39.24) | 52 (34.21) | |
| Local | 148 (64.07) | 48 (60.76) | 100 (65.79) | |
| Reperfusion status, n(%) | ||||
| mTICI | ||||
| 0–2a | 42 (18.18) | 5 (6.33) | 37 (24.34) | 0.009 |
| 2b−3a | 189 (81.18) | 74 (93.67) | 115 (75.66) | |
| Treatment delay, median (IQR), min | ||||
| Onset to puncture | 324.5 (230.5, 494.2) | 266.0 (172.0, 384.0) | 354.0 (250.0, 506.0) | 0.005 |
| Puncture to recanalization | 103.0 (69.5, 144.5) | 86.0 (60.0, 120.0) | 113.0 (79.0, 167.0) | <0.001 |
| Onset to recanalization | 449.0 (326.0, 627.7) | 365.0 (279.0, 499.0) | 485.0 (365.0, 649.0) | <0.001 |
a
mTICI score of 2b or 3 indicates satisfied recanalization.
BA, basilar artery; mTICI, modified thrombolysis in cerebral infarction; PCA, posterior cerebral artery; V4, V4 segment of vertebral artery; CE, cardioembolism; NIHSS, National Institutes of Health Stroke Scale; PC-ASPECTS, posterior circulation Alberta Stroke Program Early CT Score; SBP, systolic blood pressure; DBP, diastolic blood pressure; SOE, stroke of other determined cause; SUE, stroke of undetermined cause; TIA, transient ischemic attack; TOAST, Trial of ORG 10172 in Acute Stroke Treatment; BPV, brain parenchymal volume; CFV, cerebrospinal fluid volume.